Professional
Added to YB: 2024-02-26
Pitch date: 2024-02-25
BMY [bearish]
Bristol-Myers Squibb Company
-27.11%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Market Cap
N/A
Pitch Price
$45.73
Price Target
N/A
Dividend
4.41%
EV/EBITDA
7.85
P/E
16.00
EV/Sales
3.14
Sector
Pharmaceuticals
Category
N/A
Show full summary:
Aristotle Capital Core Equity Sold Position - Bristol-Myers
BMY sold post Q3: New product portfolio miss & lower 2025 target. Heavy patent cliff exposure made new launches crucial, but some underperformed while others faced scale challenges. Lower margin guide for more R&D spend disappointing given cheap valuation, defensive posture wanted.
Read full article (1 min)